{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-24T01:08:18.314Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-24. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-24. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-24, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED FROM PRIOR CLOSED IDEAS (apply when scoring this candidate):\n  - [anti_signal, conf 5] In low-float, high-short-interest commodity names (~10%+ shorts), pre-earnings positioning can cause large directional spikes (10-15%) that distort entry pricing and skew readings. These spikes are driven by gamma positioning and short-covering, not fundamental information. Enter spreads AFTER the pre-event spike resolves, not before.\n      applies: Applies to commodity-linked names with short interest >10% and market cap <$10B entering earnings. Does NOT apply to large-cap names with low short interest where positioning is more efficient.\n  - [catalyst, conf 5] For pre-revenue mining companies, the key earnings catalyst is operational progress (mine start-up, production targets, permitting status), not EPS. EPS misses are expected and priced in. Market reaction is driven by whether operational milestones are met or delayed, not financial performance. Score catalysts based on operational milestone significance, not EPS surprise potential.\n      applies: Applies to all pre-revenue or early-stage mining/exploration companies. Does NOT apply to established producers where EPS and revenue are the primary drivers.\n  - [anti_signal, conf 5] When RSI(14) > 80 AND the stock has run up >40% in 180 days entering earnings, the probability of mean-reversion is high regardless of implied move richness. The direction_evidence score should be reduced by at least 5 points, and the trade should be avoided unless there is a strong contrarian catalyst.\n      applies: Applies to any earnings play where RSI > 80 and the stock has run up >40% in the prior 180 days. Does NOT apply when the stock is near its 200-DMA or has been consolidating.\n  - [structure, conf 5] If the options chain has null bid/ask data across all strikes, the implied move calculation is unreliable. The scout should flag this as a fatal flaw and reject the trade — do not proceed with assumed implied move metrics.\n      applies: Applies to any options-based trade where the implied move is a key input. Does NOT apply to trades that do not rely on implied move calculations.\n  - [structure, conf 4] For zero-revenue resource companies, earnings reports are operational milestone updates, not financial performance events. Market reaction is typically delayed 3-7 days as analysts digest operational details (mine start-up, production targets, inventory decisions). Use longer-dated options (7-14 DTE) or calendar spreads instead of tight DTE spreads that expire before the full reaction.\n      applies: Applies to all pre-revenue or zero-revenue resource/mining companies where operational milestones (mine start-up, production ramp, permitting) drive valuations. Does NOT apply to established producers with consistent revenue where earnings reactions are immediate.\n  - [smart_money, conf 4] In cybersecurity names during AI-capex peaks, executive sales (even Rule 10b5-1) at prices significantly below current spot should be weighted more heavily than analyst upgrades. Insiders are closer to the data and may be positioning for a plateau.\n      applies: Applies to cybersecurity and AI-infrastructure names during periods of elevated analyst optimism. Does NOT apply when insiders are buying or when sales are at prices near current spot.\n  - [catalyst, conf 4] Historical EPS beats do not guarantee positive stock reaction if the stock has already run up into the event. The 'beat' is priced in, and any 'in-line' result is a disappointment. The catalyst_was_real score should be reduced when the pre-event run-up exceeds 20%.\n      applies: Applies to any earnings play where the stock has run up >20% into the event. Does NOT apply when the stock has been consolidating or declining into the event.\n  - [smart_money, conf 3] In commodity-linked names with institutional holders, put skew is often driven by hedging activity (portfolio insurance, commodity price exposure) rather than directional bearishness. Elevated put skew in these names should be discounted as a signal and treated as structural, not informational.\n      applies: Applies to all commodity-linked names (uranium, copper, lithium, oil) where institutional holders hedge commodity price exposure via options. Does NOT apply to pure-play companies with no commodity exposure where skew reflects genuine directional views.\n\nDOSSIER:\n{\n  \"symbol\": \"GKOS\",\n  \"company\": \"Glaukos Corporation\",\n  \"investigation_summary\": \"The investigation trigger was a cluster of 30 Form 4 filings in 14 days, but upon detailed reading all were routine director RSU grants (vested at $0) from the May 28 annual meeting — zero open-market purchases confirmed. Two notable selling events exist: CEO/CFO Navratil executed Rule 10b5-1 sales of ~$200K on April 10 and a final tranche of ~$201K on June 16, while COO Gilliam sold $2.8M on May 1 near the 52-week high ($143.54). The stock is within 9% of its all-time high, has run +34% YTD, and trades at an extreme forward P/E of 303x with negative FCF — a classic fully-valued mega-cap growth/medtech profile where IV elevation (50-60%) makes income strategies the only structure worth pursuing. No material mispricing was identified; no edge in data.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 5,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company ($7.9B market cap) focused on glaucoma, corneal disorders, and retinal diseases. Core products include the iStent family of micro-bypass stents (83% of 2025 net sales), iDose TR sustained-release travoprost implant approved Dec 2023 and ramping commercialized in 2024-25, and Epioxa FDA-approved October 2025 for keratoconus without epithelium removal. The company generated record Q1 2026 net sales of $150.6M (+41% YoY), beating estimates by 10%, while still posting a per-share loss. iDose TR reimbursement from Medicare MACs remains a work in progress, and international expansion (EU MDR certification for iStent infinite) is underway. The balance sheet carries ~$105M debt vs $277M cash; FCF turned slightly positive ($6.1M TTM). The forward P/E of 303x reflects substantial pipeline optionality embedded in current valuation.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 3235000,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-07-29\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026: -$0.18 actual vs -$0.28 est (+36% beat); Q4 2025: -$0.28 vs -$0.20 est (-43% miss — the stock gapped down). Pattern is mixed.\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 earnings July 29, 2026 — first look at full-year revenue guidance sustainability post-Q1 beat and Epioxa commercial launch progress in H2 2025/FY2026\",\n          \"date_or_window\": \"July 29, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/glaukos-announces-first-quarter-2026-200500484.html\"\n          ],\n          \"directional_bias\": \"ambiguous\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"iDose TR Medicare MAC reimbursement normalization — ongoing throughout H1 2026 with MACs, affecting procedure-level revenue recognition\",\n          \"date_or_window\": \"H1 2026 (ongoing)\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"Epioxa commercial launch — FDA approved October 2025 for iLink epi-on keratoconus; H1 2026 launch data expected near Q2 earnings\",\n          \"date_or_window\": \"H1 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"iStent infinite EU MDR certification received June 2025; European commercial launch ongoing — early revenue contribution in 2026\",\n          \"date_or_window\": \"H2 2025 onward\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 303.52,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -174.79,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 0.08,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"GKOS trades at 303x forward P/E with negative EBITDA and FCF — extreme premium justified by pipeline optionality (retinal programs, PRESERFLO Phase 3, iDose extended-release). At ~$135 near the 52-week high ($148.11), there is no mispricing; the market has priced in substantial success across multiple programs simultaneously. This is a fully-valued story where only income strategies on pullbacks are warranted.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": 78.08,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 60.4,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 134.65,\n    \"ytd_return_pct\": 34.38,\n    \"from_52w_high_pct\": 9.08\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-23\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY 2025 net sales $551.3M (+41% YoY); iStent family + accessories ~83%, corneal health (Photrexa/iLink) ~17%; iDose TR launched Q1 2024 with Medicare J-code; Epioxa FDA-approved October 2025 for keratoconus epi-on CXL; iStent infinite EU MDR certification June 2025; PRESERFLO MicroShunt Phase 3 initiated 2025; Mobius Therapeutics acquired May 2025 (Mitosol); gross margin ~78%; still net-loss company with improving FCF; $277M cash vs $106M debt\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-04-30\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526193004/gkos-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: Record net sales $150.6M (+41% YoY); iDose TR reimbursement continues to normalize with MACs; Epioxa commercial launch preparation ongoing for H1 2026; full-year 2026 revenue guidance raised\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-03\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526255758/gkos-20260528.htm\",\n      \"key_takeaways\": [\n        \"May 28, 2026 annual meeting: all three proposals passed; Denice Torres and Aimee Weisner re-elected as directors; say-on-pay approved (87% FOR); Ernst & Young ratified\"\n      ]\n    },\n    {\n      \"form\": \"4\",\n      \"filed\": \"2026-06-18\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000192005326000020/xslF345X06/form4-06182026_110637.xml\",\n      \"key_takeaways\": [\n        \"CEO/CFO Navratil SOLD 1,537 shares at $130.68 (code S) via Rule 10b5-1 plan adopted March 12, 2026 — not a discretionary buy signal\"\n      ]\n    },\n    {\n      \"form\": \"4\",\n      \"filed\": \"2026-05-04\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000170585026000018/xslF345X06/form4-05042026_100505.xml\",\n      \"key_takeaways\": [\n        \"COO Gilliam SOLD 19,573 shares at $143.54 (code S) — ~$2.81M near the 52-week high; not a discretionary buy\"\n      ]\n    },\n    {\n      \"form\": \"Multiple Form 4s from June 1, 2026\",\n      \"filed\": \"2026-06-01\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000184759826000006/xslF345X06/form4-06012026_100644.xml\",\n      \"key_takeaways\": [\n        \"9 directors received RSU grants of ~1,878 shares each (code A) at $0 on May 28 as part of director compensation policy — NOT open-market purchases; routine annual vesting\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-07-17\",\n      \"2026-08-21\"\n    ],\n    \"iv_summary\": \"ATM IV: ~50% Aug / ~55% Jul. OTM put skew elevated (135 put at 54.5% vs 130 call at 50.8%), suggesting cautious hedging demand below spot.\",\n    \"notable_skew_or_flow\": \"Put/call ratio on near-term is slightly bearish (1.33); no whale blocks identified; top OI strikes: 125p/3, 140c/131 — a wide neutral band consistent with range-bound expectations rather than directional conviction\"\n  },\n  \"competitive_landscape\": \"GKOS occupies MIGS leadership via iStent/iStent inject W /iStent infinite vs Alcon, Sight Sciences, AbbVie. In procedural pharmaceuticals, iDose TR competes with Allergan (AbbVie) eye drops. The corneal CXL franchise faces compounding pharmacies and Epion; retinal programs against Genentech/Roche, Regeneron, Novartis. Scale of competition increases significantly if PRESERFLO reaches Phase 3 completion — competitive pool widens to all surgical glaucoma interventions.\",\n  \"key_risks\": [\n    \"iDose TR MAC reimbursement normalization could take longer than guided\",\n    \"Epioxa commercial uptake in H1 2026 launch window is unproven; pricing and patient volume uncertain\",\n    \"Retinal programs (GLK-401 multi-kinase inhibitor, GLK-411) are Phase 1/2 — binary regulatory risk significant\",\n    \"Valuation extreme at 303x forward P/E with negative FCF creates vulnerability to multiple compression on any disappointment\",\n    \"PRESERFLO MicroShunt Phase 3 is early-stage; FDA approval path carries uncertainty\",\n    \"International expansion (EU launch) adds regulatory complexity and currency headwinds\"\n  ],\n  \"what_the_market_might_be_missing\": \"Nothing material identified. The investigation trigger of 30 Form 4s was a cluster of routine annual director RSU grants with zero discretionary open-market purchases — the opposite of a bullish insider signal. CEO and COO have been selling at elevated prices ($143-144 range in May), which is consistent with fully-valued behavior by insiders rather than conviction buying.\",\n  \"anti_signals\": [\n    \"dilution\",\n    \"accounting\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"10-K FY2025\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm\"\n    },\n    {\n      \"label\": \"Q1 2026 earnings press release\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/glaukos-announces-first-quarter-2026-200500484.html\"\n    },\n    {\n      \"label\": \"Form 4 - CEO/CFO Navratil June 16, 2026 sale\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000192005326000020/xslF345X06/form4-06182026_110637.xml\"\n    },\n    {\n      \"label\": \"Form 4 - COO Gilliam May 1, 2026 sale\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000170585026000018/xslF345X06/form4-05042026_100505.xml\"\n    },\n    {\n      \"label\": \"Annual Meeting 8-K May 28, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1192448/000119312526255758/gkos-20260528.htm\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-24T01:08:48.533Z",
      "raw_content": "<think>The dossier is for GKOS (Glaukos Corporation).\nScout verdict: `range_bound_or_income`\nMarket cap: $7.9B -> `core` risk class.\nScore breakdown:\nA. Smart Money (max 25): 0 insider purchases. Material insider selling > buying ($3.2M sold, $0 bought). Penalty: -10 pts. Score: 0 (floor is 0).\nB. Options Flow / UOA (max 10): No whale blocks. Put/call ratio 1.33 bearish. No bullish IV skew. Score: 0.\nC. Catalyst (max 25): Next earnings July 29, 2026. EPS surprise pattern mixed (Q1 beat, Q4 miss). Guidance raise in last 90d: +5 pts. Named catalysts: iDose TR MAC reimbursement, Epioxa launch. But catalyst score caps at 25. Let's give it 5 for guidance raise. Maybe 8 for product/reimbursement catalysts? The dossier says \"first look at full-year revenue guidance sustainability post-Q1 beat\". I'll give it 8 pts for product/reimbursement catalysts. Total: 13.\nD. Mispricing (max 15): Forward P/E 303x. EV/EBITDA -174. FCF yield 0.08%. No mispricing. Score: 0.\nE. Quality (max 15): ROIC null. Gross margin 78.08% (no YoY trend given, just a number). Net debt/EBITDA null. Balance sheet grade A. Score: 0 (or maybe 5 for balance sheet? I'll stick to 0 for strict rubric).\nF. Momentum/Technical (max 10): Above 50DMA and 200DMA: +3 pts. RSI 60.4: +2 pts. MACD bullish cross: +1 pt. 12-1 momentum null. Total: 6 pts.\n\nTotal Score: ~24.\nAnti-signals: \"dilution\", \"accounting\". The dossier says \"dilution\" and \"accounting\" but doesn't elaborate heavily, but the prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I'll skip due to low score, extreme valuation, insider selling, and lack of edge.\nEdge check: \"Nothing material identified. The investigation trigger... was routine director RSU grants... opposite of bullish insider signal.\" \"At ~$135 near the 52-week high... there is no mispricing; the market has priced in substantial success... This is a fully-valued story where only income strategies on pullbacks are warranted.\" But even income strategies aren't compelling here given the premium context and lack of clear range thesis. The prompt says \"Mediocre publishes burn Devil's Advocate budget... Most dossiers should return skip\".\nI will skip with a score around 25-30.\n\nLet's compute strictly:\nA: 0\nB: 0\nC: 8 (product/reimbursement catalysts)\nD: 0\nE: 0\nF: 6\nTotal: 14.\nScore is well below 45.\nReason: Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no edge.\nI will output the skip JSON.\nCheck thresholds: ASYMMETRIC vs CORE. Market cap $7.9B -> CORE.\nThreshold < 45 -> Skip.\nAll good.\nOutput matches format.\nProceed. \nLet's double check the anti-signal gate: \"dilution\", \"accounting\". The dossier lists them but doesn't give details. I'll just note the low score and lack of edge as the primary reason, which is sufficient.\nI will formulate the JSON.\nScore breakdown: smart_money: 0, options_flow: 0, catalyst: 8, mispricing: 0, quality: 0, technical: 6. Total: 14.\nReason: \"Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no actionable edge.\"\nMatches requirements.\nOutput only JSON.\nDone. \nSelf-Correction/Refinement during thought:\nWait, the prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I should acknowledge the anti-signals briefly or just rely on the low score. The low score is sufficient. I'll stick to the low score.\nI will output exactly the skip JSON.\nCheck structure:\n{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": { ... },\n  \"reason\": \"...\"\n}\nAll good. \nProceeds. \nOutput matches. \n[Done] \nOutput Generation. \n(Note: I'll make sure the JSON is perfectly formatted.) \nScore: 14. Breakdown: 0, 0, 8, 0, 0, 6. \nReason: As drafted. \nReady. \nOutput matches request. \nProceeds. \n```json\n{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no actionable edge.\"\n}\n```\nWait, checking the prompt: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I'll add a note about the anti-signals in the reason if needed, but the low score is definitive. I'll keep it concise.\nAll good.\nOutput matches. \nProceeds. \n(Self-Correction/Verification during generation prep)\nLet's verify the score breakdown sums to 14.\nA: 0\nB: 0\nC: 8\nD: 0\nE: 0\nF: 6\nSum: 14. Correct.\nRisk class: core (>$5B).\nThreshold <45: Skip. Correct.\nOutput matches schema exactly.\nDone. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no actionable edge.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no actionable edge.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Extreme valuation (303x FWD P/E), material insider selling ($3.2M vs $0 buys), and absence of asymmetric upside or clear income structure setup make this a non-starter. The market has fully priced in near-term catalysts, and the lack of mispricing or smart-money support provides no actionable edge.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 30219,
  "stop_reason": "stop",
  "completed_at": "2026-06-24T01:08:48.533Z"
}